Amifostine and hematologic effects.
Artículo
en Inglés
| IMSEAR
| ID: sea-45470
ABSTRACT
Amifostine is a protective agent of normal tissue from adverse effects of radiochemotherapy. It is the prodrug that is dephosphorylated by alkaline phosphatase on plasma membrane into the active form named WR-1065. More than 90 per cent of the drug is cleared from plasma in 6 minutes and the peak tissue concentration is 10-30 minutes after intravenous administration. Amifostine has the selective property to protect normal tissue but not cancer cells by mainly scavenging free radicals induced by radiation and chemocytotoxic agents. Both preclinical and clinical studies of this drug provide the significant protection of hematopoietic progentitors from a broad range of cytotoxic agents such as cyclophosphamide, cisplatin, vinblastine, carboplatin, mitomycin-C, fotemustine, doxorubicin, daunorubicin and radiation as well. Moreover, this drug can protect other normal organs or tissues including kidney, salivary gland, liver, heart, lung and small intestine. Amifostine is quite safe, the two major side effects are vomiting and hypotension, and the minor effects are flushing, sneezing, dizziness, chills, metallic taste etc. The drug was approved by the FDA of U.S.A. for use as a cytoprotectant in cyclophosphamide and cisplatin treatment for advanced ovarian cancer and non small cell lung cancer.
Texto completo:
Disponible
Índice:
IMSEAR (Asia Sudoriental)
Asunto principal:
Protectores contra Radiación
/
Radioterapia
/
Infusiones Intravenosas
/
Humanos
/
Protocolos de Quimioterapia Combinada Antineoplásica
/
Ensayos Clínicos como Asunto
/
Sensibilidad y Especificidad
/
Amifostina
/
Relación Dosis-Respuesta a Droga
/
Enfermedades Hematológicas
Tipo de estudio:
Estudio diagnóstico
Idioma:
Inglés
Año:
2000
Tipo del documento:
Artículo
Similares
MEDLINE
...
LILACS
LIS